WO2010058679A1 - 骨折修復促進剤 - Google Patents
骨折修復促進剤 Download PDFInfo
- Publication number
- WO2010058679A1 WO2010058679A1 PCT/JP2009/068295 JP2009068295W WO2010058679A1 WO 2010058679 A1 WO2010058679 A1 WO 2010058679A1 JP 2009068295 W JP2009068295 W JP 2009068295W WO 2010058679 A1 WO2010058679 A1 WO 2010058679A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- milk
- basic protein
- fracture repair
- fraction
- fracture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
- A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
- A21D2/24—Organic nitrogen compounds
- A21D2/26—Proteins
- A21D2/261—Animal proteins
- A21D2/263—Animal proteins from dairy products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/068—Particular types of cheese
- A23C19/08—Process cheese preparations; Making thereof, e.g. melting, emulsifying, sterilizing
- A23C19/082—Adding substances to the curd before or during melting; Melting salts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a fracture repair accelerator, a method for producing the same, a food and drink containing the fracture repair accelerator, and a feed.
- the fracture repair-promoting agent of the present invention has an action of promoting multistage reactions such as inflammation, cartilage formation or subperiosteal bone formation, angiogenesis, and bone remodeling, which are repair reactions of fracture sites. Therefore, the fracture repair promoter of the present invention is useful for the treatment of fractures.
- osteoporosis In recent years, with the aging of the population, bone-related risks such as osteoporosis and fractures tend to increase. In bone tissue, bone formation by osteoblasts and bone resorption by osteoclasts are constantly working in a well-balanced manner. However, the balance is not maintained and a disease that appears as a result of leaning to bone resorption is osteoporosis. In particular, in older women, the role of osteoclasts that resorb bone predominates after menopause due to the lack of estrogen secretion. To prevent osteoporosis, it is necessary to take measures to maintain bone mass. Vitamin D preparations and the like have been disclosed as pharmaceuticals for alleviating bone loss and fracture incidence in osteoporosis.
- Non-Patent Document 1 Non-Patent Document 1
- Non-Patent Document 2 Fracture healing occurs through processes such as inflammation, callus formation, collagen production of chondrocytes in the callus, angiogenesis, and bone remodeling.
- bone formation is performed by the action of osteoblasts and only plays a part in the fracture healing process.
- factors that affect osteoblast differentiation and proliferation include cbfa-1, FGF-1, FGF-2, milk-derived basic protein fractions, and the like (see, for example, Patent Document 1 and Non-Patent Document 3).
- a fracture site When a bone is not able to withstand external forces and a fracture is caused, the fracture site is repaired through processes such as inflammation of the fracture site, formation of a callus, angiogenesis, and bone remodeling.
- repairing a fracture site is a complex reaction in bone tissue including blood vessels and nerves. Therefore, it is unclear whether it has the effect of promoting the healing process of fracture, which is a complex reaction system, simply by promoting bone formation via osteoblasts.
- the recovery of the fracture may not be accelerated. That is, the above-described substances are pharmacological actions only in the part of forming bones, and it is not clear whether a series of reactions for fracture repair is promoted.
- an object of the present invention is to provide a fracture repair accelerator that accelerates repair of a fracture site by ingestion, a method for producing the same, a food and drink that contains the fracture repair accelerator, and a feed.
- this invention is invention which consists of either of the following structures.
- a fracture repair promoter comprising a milk-derived basic protein fraction as an active ingredient.
- a fracture repair promoter comprising as an active ingredient a basic peptide fraction obtained by degrading the milk-derived basic protein fraction according to (1) or (2) with a proteolytic enzyme.
- the proteolytic enzyme is at least one proteolytic enzyme selected from the group consisting of pepsin, trypsin and chymotrypsin.
- Milk or a milk-derived raw material is brought into contact with a cation exchange resin to adsorb basic proteins, and a fraction adsorbed on the resin is eluted with an eluent having a salt concentration of 0.1 M to 1.0 M.
- a method for producing a fracture repair accelerator comprising the obtained milk-derived basic protein fraction as an active ingredient.
- Milk or a raw material derived from milk is brought into contact with a cation exchange resin to adsorb basic protein, and a fraction adsorbed on this resin is eluted with an eluent having a salt concentration of 0.1 M to 1.0 M to obtain
- a method for producing a fracture repair accelerator comprising a basic peptide fraction obtained by degrading a milk-derived basic protein fraction with a proteolytic enzyme as an active ingredient.
- the fracture repair accelerator of the present invention has a remarkable fracture repair action at the fracture site and is useful for the treatment of fractures due to external force, illness, and fatigue. Moreover, the fracture repair promoter of the present invention can be easily taken orally.
- the fracture repair accelerator of the present invention is derived from milk and can be taken with peace of mind.
- the feature of the fracture repair accelerator of the present invention is that a basic protein fraction derived from milk or a basic peptide fraction obtained by degrading a basic protein fraction with a proteolytic enzyme is used as an active ingredient.
- This milk-derived basic protein fraction is obtained from milk of mammals such as cow's milk, human milk, goat milk, sheep milk, and this basic peptide fraction is a milk-derived basic protein fraction. It is obtained by acting a proteolytic enzyme on the bone, and has the effect of promoting the repair of the fracture site. Based on these actions, the treatment of fractures can be accelerated.
- the milk-derived basic protein fraction used as an active ingredient of this fracture repair accelerator has the following properties. 1) According to Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), it consists of several proteins having a molecular weight in the range of 3,000-80,000. 2) 95% by weight or more is protein and contains a small amount of other fat and ash. 3) Protein mainly consists of lactoferrin and lactoperoxidase. 4) The amino acid composition of the protein contains 15% by weight or more of basic amino acids such as lysine, histidine and arginine.
- SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis
- Such a basic protein fraction is obtained by, for example, bringing a milk material such as skim milk or whey into contact with a cation exchange resin to adsorb the basic protein, and the basic protein fraction adsorbed on this resin is reduced to 0.00. Elution with 1M-1.0M salt eluate, collect this elution fraction, desalinate and concentrate by reverse osmosis (RO) membrane, electrodialysis (ED) method, etc., and dry as necessary Can be obtained.
- RO reverse osmosis
- ED electrodialysis
- a method for obtaining a protein fraction by elution with an eluent exceeding pH 5 and an ionic strength exceeding 0.5 Japanese Patent Laid-Open No. 5-202098
- a method using alginate gel Japanese Patent Laid-Open No. 61-246198]
- a method of obtaining from whey using inorganic porous particles Japanese Patent Laid-Open No. 1-86839
- a method of obtaining from milk using a sulfated ester compound Japanese Patent Laid-Open No. 63-255300
- the basic protein fraction obtained by such a method can be used.
- the basic peptide fraction derived from milk has the same amino acid composition as the basic protein fraction.
- pepsin, trypsin, and the basic protein fraction derived from milk obtained by the above method are used. It can be obtained as a peptide composition having an average molecular weight of 4,000 or less by allowing a proteolytic enzyme such as chymotrypsin to act, and further allowing a proteolytic enzyme such as pancreatin to act as necessary.
- the active ingredient milk-derived basic protein fraction or basic peptide fraction can be used as it is, but according to conventional methods, powders and granules It can be formulated into tablets, capsules, drinks and the like. Furthermore, since these basic protein fractions and basic peptide fractions are relatively heat-stable, the raw material containing the milk-derived basic protein or basic peptide fraction is usually used under the conditions used. Heat sterilization is also possible.
- the dose of the fracture repair accelerator of the present invention varies depending on the age, therapeutic effect, disease state, etc., but may be ingested about 10 to 500 mg per day. Moreover, what is necessary is just to be able to mix
- the basic protein fraction and basic peptide fraction of the present invention no acute toxicity was observed in rats. Moreover, it is desirable that the basic protein fraction and the basic peptide fraction of the present invention be taken orally together with a calcium salt having good absorbability. Examples of such a calcium salt having good absorbability include calcium chloride, calcium carbonate, calcium lactate, eggshell, milk-derived calcium-containing material, and the like.
- a column (diameter 5 cm ⁇ height 30 cm) packed with 400 g of a cation exchange resin sulfonated chitopearl (Fujibo Co., Ltd.) was thoroughly washed with deionized water, and then 40 liters of unsterilized skim milk (pH 6. 7) was passed at a flow rate of 25 ml / min. After passing through the column, the column was thoroughly washed with deionized water, and the basic protein fraction adsorbed on the resin was eluted with 0.02 M carbonate buffer (pH 7.0) containing 0.98 M sodium chloride.
- 0.02 M carbonate buffer pH 7.0
- the eluate was desalted with a reverse osmosis (RO) membrane, concentrated, and lyophilized to obtain 21 g of a powdery basic protein fraction.
- This basic protein fraction can be used as it is as a fracture repair accelerator of the present invention.
- Example 1 When the basic protein fraction obtained in Example 1 was measured by sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) electrophoresis, the molecular weight was distributed in the range of 3,000-80,000.
- SDS-PAGE sodium dodecyl sulfate-polyacrylamide
- Example 2 The component composition of the basic protein fraction obtained in Example 1 was analyzed. The results are shown in Table 1. As shown in this table, most of this fraction is protein.
- Example 3 The protein composition of the basic protein fraction obtained in Example 1 was analyzed. The results are shown in Table 2. This basic protein fraction contains 40% by weight or more of lactoferrin and lactoperoxidase.
- Example 4 The basic protein fraction obtained in Example 1 was hydrolyzed with 6N hydrochloric acid at 110 ° C. for 24 hours, and then the amino acid composition was analyzed with an amino acid analyzer (L-8500 type, manufactured by Hitachi, Ltd.). The results are shown in Table 3. This basic protein fraction contains 15% by weight or more of basic amino acids in the amino acid composition.
- An acidic polysaccharide gel made of carrageenan was processed into beads (Japanese Unexamined Patent Publication No. 61-246198), and a column (diameter 100 cm ⁇ height 20 cm) packed with 50 kg was sufficiently washed with deionized water. 3000 liters of skim milk (pH 6.7) was passed through this column at a flow rate of 25 ml / min. After passing through the column, the column was thoroughly washed with deionized water, and the basic protein fraction adsorbed on the resin was eluted with 0.02 M carbonate buffer (pH 7.0) containing 1.5 M sodium chloride.
- the eluate was desalted with a reverse osmosis (RO) membrane, concentrated, and lyophilized to obtain 136 g of powdery basic protein fraction powder.
- This basic protein fraction can be used as it is as a fracture repair accelerator of the present invention.
- the right tibia was not subjected to a fracture, and a needle was inserted into the medullary cavity to form a sham operation group. After confirming awakening after the operation, administration of the basic protein fraction was started.
- the experiment was conducted as three groups: a non-administration group (CTRL), a 0.165% administration group, and a 1% administration group.
- CTRL non-administration group
- the basic protein fraction was administered orally and in a form dissolved in drinking water. In order to prevent spoilage, the basic protein fraction was replaced with a new one every two days.
- the evaluation of fracture repair was 4 weeks after the operation. The mice were perfused and fixed during deep anesthesia, photographed with soft X-rays (Softex, Tokyo), and then ⁇ CT was photographed to evaluate the fracture recovery state.
- the biomechanical analysis measured the mechanical strength of the tibia 4 weeks after using the electronic measurement control type precision universal material testing machine (autograph). The measurement item evaluated total energy (toughness: resistance to failure, total area of stress-s
- FIG. 1 shows soft X-ray images (4 weeks after surgery) of mouse fracture models in the group not administered with the basic protein fraction (CTRL) and the group administered with 1%. From the results of FIG. 1, it was revealed that the bone density around the fracture line was higher in the basic protein fraction administration group.
- CTRL basic protein fraction
- FIG. 2 shows a ⁇ CT image of a mouse fracture model. Areas showing high BMD (Bone Mineral Density) values are shown in warm colors, and areas showing low BMD values are shown in cold colors. The fracture site is indicated by a white arrow. In the basic protein fraction administration group, the area around the fracture site showed high BMD, and the fracture repair tended to be clearly promoted.
- BMD Battery Mineral Density
- FIG. 3 shows the total energy representing bone toughness. It was revealed that administration of the basic protein fraction increased the total energy as compared to the basic protein fraction non-administered group (CTRL). Moreover, in the 1% basic protein fraction administration group, a significantly high value was shown. Therefore, it was revealed that the group to which the basic protein fraction was administered promoted fracture repair compared to the non-administered group. In addition, although the experimental result was not shown, the same effect was recognized when the basic peptide fraction obtained in Example 4 and Example 5 was used.
- CTRL basic protein fraction non-administered group
- Example 1 Each component was mixed with the composition shown in Table 4, and pressure-molded to prepare a tablet having a fracture repair-promoting action containing the milk-derived basic protein fraction obtained in Example 1.
- Example 1 After mixing each component with the composition shown in Table 6 and filling it in a container, it is heat sterilized to prepare a jelly having a fracture repair promoting action containing the milk-derived basic protein fraction obtained in Example 1 did.
- Each component was mixed with the composition shown in Table 7, emulsified at an emulsification temperature of 85 ° C., and a process cheese having a fracture repair promoting action containing the milk-derived basic protein fraction obtained in Example 1 was prepared. .
- Example 1 Each component was mixed with the composition shown in Table 9, and a feed for breeding dogs having a fracture repair promoting action containing the milk-derived basic protein fraction obtained in Example 1 was prepared.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Husbandry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
しかし、前述のビタミンD製剤は高齢者を対象とした試験で、ビタミンDが充足している人にとっては、骨折の治癒の助けになるという証拠はないという主張もある(例えば、非特許文献1、非特許文献2参照)。また、骨折の治癒は炎症、仮骨の形成、仮骨中の軟骨細胞のコラーゲン産生、血管新生、骨リモデリングという過程を経て起こる。一方で骨の形成は骨芽細胞の働きによって行われ、骨折治癒過程の一端を担っているのみである。骨芽細胞の分化、増殖に作用する因子としては、cbfa−1、FGF−1、FGF−2、乳由来塩基性タンパク質画分等が挙げられる(例えば、特許文献1、非特許文献3参照)。しかし、骨折部位の修復は、血管や神経も含む骨組織における複雑な反応である。よって、単に骨芽細胞を介して骨の形成を促進するだけでは複雑な反応系である骨折の治癒という過程を促進させうる作用を持つかどうかは不明である。例えば、FGF−2は骨芽細胞の増殖については促進する作用があるものの、骨芽細胞の分化および軟骨細胞におけるコラーゲンの産生に対しては負に制御する(例えば、非特許文献4参照)。
骨折の治療は、単純骨折の場合は器具を用いて骨折箇所を固定し、骨の転位がある場合には牽引や手術による整復術によって正常な位置に戻した上で、少なくとも3週間から1月という一定期間の固定と安静を保つことが一般的に行われている。このように骨折の治癒には時間を要することから、よりよい骨折修復促進剤により骨折の治癒を促進し、固定や安静を保たなければならない期間を短縮することが患者の負担を軽減し、医療費の削減にもつながる。現状では経口により簡便に摂取できる骨折修復促進剤は存在せず、骨折患者や医療の立場からも広く求められている。
したがって、本発明は、摂取することで骨折部位の修復を早める骨折修復促進剤及びその製造方法、骨折修復促進剤を配合した飲食品、飼料を提供することを課題とする。
(1)乳由来の塩基性タンパク質画分を有効成分とする骨折修復促進剤。
(2)乳由来の塩基性タンパク質画分が、そのアミノ酸組成中に塩基性アミノ酸を15重量%以上含有している画分である(1)記載の骨折修復促進剤。
(3)(1)又は(2)に記載の乳由来の塩基性タンパク質画分をタンパク質分解酵素で分解して得られる塩基性ペプチド画分を有効成分とする骨折修復促進剤。
(4)前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素である(3)記載の骨折修復促進剤。
(5)前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素とパンクレアチンである(3)記載の骨折修復促進剤。
(6)(1)~(5)のいずれかに記載の乳由来の塩基性タンパク質画分又は塩基性ペプチド画分を配合した飲食品。
(7)(1)~(5)のいずれかに記載の乳由来の塩基性タンパク質画分又は塩基性ペプチド画分を配合した飼料。
(8)乳又は乳由来の原料を陽イオン交換樹脂に接触させて塩基性タンパク質を吸着させ、この樹脂に吸着した画分を塩濃度0.1M~1.0Mの溶出液で溶出して得られる乳由来塩基性タンパク質画分を有効成分とする骨折修復促進剤の製造方法。
(9)乳又は乳由来の原料を陽イオン交換樹脂に接触させて塩基性タンパク質を吸着させ、この樹脂に吸着した画分を塩濃度0.1M~1.0Mの溶出液で溶出し、得られる乳由来塩基性タンパク質画分をタンパク質分解酵素で分解して得られる塩基性ペプチド画分を有効成分とする骨折修復促進剤の製造方法。
(10)前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素である(9)記載の骨折修復促進剤の製造方法。
(11)前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素とパンクレアチンである(9)記載の骨折修復促進剤の製造方法。
1)Sodium Dodecyl Sulfate Polyacrylamid Gel Electrophoresis(SDS−PAGE)によると分子量3,000~80,000の範囲の数種のタンパク質よりなる。
2)95重量%以上がタンパク質であって、その他少量の脂肪、灰分を含む。
3)タンパク質は主としてラクトフェリン及びラクトパーオキシダーゼよりなる。
4)タンパク質のアミノ酸組成は、リジン、ヒスチジン、アルギニン等の塩基性アミノ酸を15重量%以上含有する。
また、乳由来の塩基性タンパク質画分を得る方法としては、乳又は乳由来の原料を陽イオン交換体に接触させて塩基性タンパク質を吸着させた後、この陽イオン交換体に吸着した塩基性タンパク質画分を、pH5を越え、イオン強度0.5を越える溶出液で溶出して得る方法〔特開平5−202098号公報〕、アルギン酸ゲルを用いて得る方法〔特開昭61−246198号公報〕、無機の多孔性粒子を用いて乳清から得る方法〔特開平1−86839号公報〕、硫酸化エステル化合物を用いて乳から得る方法〔特開昭63−255300号公報〕等が知られており、本発明では、このような方法で得られた塩基性タンパク質画分を用いることができる。
実施例1で得られた塩基性タンパク質画分について、ソジウムドデシルサルフェート−ポリアクリルアミド(SDS−PAGE)電気泳動により測定したところ、分子量は3,000~80,000の範囲に分布していた。
実施例1で得られた塩基性タンパク質画分について、成分組成を分析した。その結果を表1に示す。この表に示すとおり、この画分のほとんどはタンパク質である。
実施例1で得られた塩基性タンパク質画分について、そのタンパク質組成を分析した。その結果を表2に示す。この塩基性タンパク質画分には、40重量%以上のラクトフェリン及びラクトパーオキシダーゼが含まれている。
実施例1で得られた塩基性タンパク質画分について、6N塩酸で110℃、24時間加水分解した後、アミノ酸分析装置(L−8500型、日立製作所製)でそのアミノ酸組成を分析した。その結果を表3に示す。この塩基性タンパク質画分には、アミノ酸組成中15重量%以上の塩基性アミノ酸が含まれている。
(動物実験)
実施例1で得られた塩基性タンパク質画分を用いて動物実験を行った。
実験には6週齢の雄性マウス(C3H/HeJ)を用いた。ジエチルエーテルで吸入麻酔後、ペントバルビタールを腹腔内に投与、麻酔下に処置をおこなった。マウスの左脛骨前面を剃毛、消毒し、15mmの切開を入れ、鈍的に剥離し脛骨を露出、膝蓋靱帯より5mm下方で、ダイヤモンドディスクを用いて、脛骨を長軸に直交するように切断し、骨折を作製した。整復後、25Gの注射針を髄腔内へ刺入し固定を行った。筋肉及び皮膚は4−0絹糸で縫合した。右脛骨は骨折を施さずに髄腔に注射針を刺入し、偽手術群とした。手術後覚醒したのを確認し、塩基性タンパク質画分の投与を開始した。非投与群(CTRL)、0.165%投与群、1%投与群の3群として実験を行った。塩基性タンパク質画分は、経口で、かつ、飲料水に溶かした形態で投与した。腐敗を防ぐため、塩基性タンパク質画分は2日毎に新しいものと交換した。
骨折修復の評価は術後4週で、深麻酔時にマウスを灌流固定し、ソフトX線(Softex,Tokyo)にて撮影、その後μCTを撮影し、骨折の回復状態を評価した。
なお、生体力学的分析は、電子計測制御式精密万能材料試験機(オートグラフ)を用い、4週後の脛骨の機械的強度を測定した。測定項目は、総エネルギー(靭性:破壊に至るまでの抵抗、応力ひずみ曲線の全面積)を評価した。
図1には、塩基性タンパク質画分非投与群(CTRL)及び1%投与群のマウス骨折モデルの軟X線像(術後4週)を示した。
図1の結果から、塩基性タンパク質画分投与群の方が、骨折線周囲の骨の密度が高いことが明らかとなった。
高いBMD(Bone Mineral Density)値を示すエリアを暖色で、低いBMD値を示すエリアを寒色で示した。骨折部位は白矢印で示した箇所である。塩基性タンパク質画分投与群では骨折部位周辺が高いBMDを示しており、骨折の修復が明らかに促進される傾向にあった。
塩基性タンパク質画分非投与群(CTRL)に比べて、塩基性タンパク質画分の投与により、総エネルギーが上昇することが明らかとなった。また、塩基性タンパク質画分1%投与群では、有意に高い値を示した。
よって、塩基性タンパク質画分を投与した群は、非投与群に比べて骨折の修復が促進されていることが明らかとなった。
なお、実験結果は示さなかったが、実施例4及び実施例5で得られた塩基性ペプチド画分を用いた場合も同様の効果が認められた。
Claims (11)
- 乳由来の塩基性タンパク質画分を有効成分とする骨折修復促進剤。
- 前記乳由来の塩基性タンパク質画分が、そのアミノ酸組成中に塩基性アミノ酸を15重量%以上含有している画分である請求項1記載の骨折修復促進剤。
- 請求項1又は2に記載の乳由来の塩基性タンパク質画分をタンパク質分解酵素で分解して得られる塩基性ペプチド画分を有効成分とする骨折修復促進剤。
- 前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素である請求項3記載の骨折修復促進剤。
- 前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素とパンクレアチンである請求項3記載の骨折修復促進剤。
- 請求項1乃至5のいずれかに記載の乳由来の塩基性タンパク質画分又は塩基性ペプチド画分を配合した飲食品。
- 請求項1乃至5のいずれかに記載の乳由来の塩基性タンパク質画分又は塩基性ペプチド画分を配合した飼料。
- 乳又は乳由来の原料を陽イオン交換樹脂に接触させて塩基性タンパク質を吸着させ、この樹脂に吸着した画分を塩濃度0.1M~1.0Mの溶出液で溶出して得られる乳由来塩基性タンパク質画分を有効成分とする骨折修復促進剤の製造方法。
- 乳又は乳由来の原料を陽イオン交換樹脂に接触させて塩基性タンパク質を吸着させ、この樹脂に吸着した画分を塩濃度0.1M~1.0Mの溶出液で溶出し、得られる乳由来塩基性タンパク質画分をタンパク質分解酵素で分解して得られる塩基性ペプチド画分を有効成分とする骨折修復促進剤の製造方法。
- 前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素である請求項9記載の骨折修復促進剤の製造方法。
- 前記タンパク質分解酵素がペプシン、トリプシン及びキモトリプシンよりなる群から選択される少なくとも1種のタンパク質分解酵素とパンクレアチンである請求項9記載の骨折修復促進剤の製造方法。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/129,613 US20120040908A1 (en) | 2008-11-18 | 2009-10-19 | Fracture repair promoter |
| JP2010539192A JPWO2010058679A1 (ja) | 2008-11-18 | 2009-10-19 | 骨折修復促進剤 |
| AU2009318621A AU2009318621A1 (en) | 2008-11-18 | 2009-10-19 | Fracture repair promoter |
| CA2743406A CA2743406A1 (en) | 2008-11-18 | 2009-10-19 | Fracture repair promoter |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008-294445 | 2008-11-18 | ||
| JP2008294445 | 2008-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010058679A1 true WO2010058679A1 (ja) | 2010-05-27 |
Family
ID=42198118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2009/068295 Ceased WO2010058679A1 (ja) | 2008-11-18 | 2009-10-19 | 骨折修復促進剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120040908A1 (ja) |
| JP (1) | JPWO2010058679A1 (ja) |
| AU (1) | AU2009318621A1 (ja) |
| CA (1) | CA2743406A1 (ja) |
| WO (1) | WO2010058679A1 (ja) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132675A1 (ja) * | 2012-03-09 | 2013-09-12 | 雪印メグミルク株式会社 | 骨強化剤 |
| WO2014020684A1 (ja) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | チーズ類及びその製造方法 |
| JPWO2014020677A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JPWO2014020680A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JPWO2014020679A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JPWO2014020678A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP2016152809A (ja) * | 2016-04-05 | 2016-08-25 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP2017121249A (ja) * | 2017-02-28 | 2017-07-13 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP2017123859A (ja) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JP2017123860A (ja) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JP2017137266A (ja) * | 2016-02-04 | 2017-08-10 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6395350B2 (ja) * | 2013-03-28 | 2018-09-26 | 雪印メグミルク株式会社 | 筋萎縮防止剤 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151331A (ja) * | 1994-09-30 | 1996-06-11 | Snow Brand Milk Prod Co Ltd | 骨強化剤 |
| JPH09191858A (ja) * | 1996-01-23 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | 塩基性タンパク質組成物、塩基性ペプチド組成物及びその利用 |
| WO2000078351A1 (en) * | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| JP2002370982A (ja) * | 2001-06-12 | 2002-12-24 | Kowa Co | 骨形成促進剤 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008214237A (ja) * | 2007-03-02 | 2008-09-18 | Snow Brand Milk Prod Co Ltd | Rankl産生抑制剤 |
| WO2008111573A1 (ja) * | 2007-03-12 | 2008-09-18 | Snow Brand Milk Products Co., Ltd. | 成長ホルモン分泌促進剤 |
| CA2704144C (en) * | 2007-11-01 | 2015-12-29 | Megmilk Snow Brand Co., Ltd. | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast |
-
2009
- 2009-10-19 WO PCT/JP2009/068295 patent/WO2010058679A1/ja not_active Ceased
- 2009-10-19 JP JP2010539192A patent/JPWO2010058679A1/ja active Pending
- 2009-10-19 AU AU2009318621A patent/AU2009318621A1/en not_active Abandoned
- 2009-10-19 CA CA2743406A patent/CA2743406A1/en not_active Abandoned
- 2009-10-19 US US13/129,613 patent/US20120040908A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08151331A (ja) * | 1994-09-30 | 1996-06-11 | Snow Brand Milk Prod Co Ltd | 骨強化剤 |
| JPH09191858A (ja) * | 1996-01-23 | 1997-07-29 | Snow Brand Milk Prod Co Ltd | 塩基性タンパク質組成物、塩基性ペプチド組成物及びその利用 |
| WO2000078351A1 (en) * | 1999-06-18 | 2000-12-28 | Mitsubishi Pharma Corporation | Osteogenesis promoters |
| JP2002370982A (ja) * | 2001-06-12 | 2002-12-24 | Kowa Co | 骨形成促進剤 |
Non-Patent Citations (2)
| Title |
|---|
| HIROSHI KAWAKAMI: "Series 'Health Claim no Kagakuteki Konkyo' -10- Gyunyu Yurai no Hone Kyoka Seibun 'MBP@' no Kino", ILSI, no. 79, July 2004 (2004-07-01), pages 11 - 17 * |
| NORIYUKI INOUE ET AL.: "Nyu Enkisei Tanpakushitsu Keiko Toyo ga Mouse Hone Keisei ni Ataeru Eikyo", DAI 17 KAI JAPANESE SOCIETY OF JUDO THERAPY SOKAI PROGRAM, 20 October 2008 (2008-10-20), pages 398 * |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013132675A1 (ja) * | 2012-03-09 | 2013-09-12 | 雪印メグミルク株式会社 | 骨強化剤 |
| JP2013184959A (ja) * | 2012-03-09 | 2013-09-19 | Snow Brand Milk Products Co Ltd | 骨強化剤 |
| TWI574695B (zh) * | 2012-03-09 | 2017-03-21 | 雪印惠乳業股份有限公司 | 骨強化劑 |
| JPWO2014020680A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| US10603362B2 (en) | 2012-07-31 | 2020-03-31 | Megmilk Snow Brand Co., Ltd. | Beverage, and method of producing the same |
| JPWO2014020679A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JPWO2014020678A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JPWO2014020677A1 (ja) * | 2012-07-31 | 2016-07-11 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| WO2014020684A1 (ja) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | チーズ類及びその製造方法 |
| US10376543B2 (en) | 2012-07-31 | 2019-08-13 | Megmilk Snow Brand Co., Ltd. | Fermented milk product and method for producing the same |
| US10485853B2 (en) | 2012-07-31 | 2019-11-26 | Megmilk Snow Brand Co., Ltd. | Cheese and method for producing the same |
| EP3935963A1 (en) | 2016-02-04 | 2022-01-12 | Megmilk Snow Brand Co., Ltd. | Food composition for improving cartilage function |
| JP2021121591A (ja) * | 2016-02-04 | 2021-08-26 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
| EP3756478A1 (en) | 2016-02-04 | 2020-12-30 | Megmilk Snow Brand Co. Ltd. | Food composition for improving cartilage function |
| JP2017137266A (ja) * | 2016-02-04 | 2017-08-10 | 雪印メグミルク株式会社 | 軟骨機能改善剤 |
| JP2016152809A (ja) * | 2016-04-05 | 2016-08-25 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
| JP2017123860A (ja) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JP2017123859A (ja) * | 2017-02-28 | 2017-07-20 | 雪印メグミルク株式会社 | 発酵乳類及びその製造方法 |
| JP2017121249A (ja) * | 2017-02-28 | 2017-07-13 | 雪印メグミルク株式会社 | 飲料及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2743406A1 (en) | 2010-05-27 |
| US20120040908A1 (en) | 2012-02-16 |
| AU2009318621A1 (en) | 2010-05-27 |
| JPWO2010058679A1 (ja) | 2012-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010058679A1 (ja) | 骨折修復促進剤 | |
| EP0704218B1 (en) | Bone reinforcing agent and foods and drinks product containing the same | |
| TWI271154B (en) | Compositions derived from milk for maintaining or improving bone health | |
| ES2215940T3 (es) | Traccion proteica basica derivada de la leche como agente para reducir la hipertension. | |
| CA2349980C (en) | Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof | |
| JPH04183371A (ja) | 骨強化食品、飼料及び医薬 | |
| JP2001346519A (ja) | 乳塩基性シスタチン高含有画分及びその分解物の製造方法 | |
| TWI586362B (zh) | 新穎蛋白質素材 | |
| JP5357042B2 (ja) | 骨強化用食品素材 | |
| JP6009181B2 (ja) | 骨強化剤 | |
| JPWO2009057287A1 (ja) | 破骨細胞形成抑制用食品素材 | |
| EP2208735B1 (en) | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast | |
| JPH09191856A (ja) | 栄養補給用組成物 | |
| JPWO2009057282A1 (ja) | 骨吸収抑制用食品素材 | |
| TWI607709B (zh) | 骨強化劑 | |
| TW201410160A (zh) | 飲料及其製造方法 | |
| JP4028177B2 (ja) | 血圧降下剤 | |
| JP4034516B2 (ja) | 脂質代謝改善剤 | |
| TWI574696B (zh) | 新穎蛋白質素材 | |
| CN113768159B (zh) | 软骨机能改善用组合物 | |
| TWI620508B (zh) | 飲料及其製造方法 | |
| WO2015008836A1 (ja) | 筋萎縮防止及び/又は筋合成促進剤 | |
| JP2017205111A (ja) | 骨疾患の予防又は治療用タンパク質素材 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09827460 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2010539192 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2009318621 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2743406 Country of ref document: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2009318621 Country of ref document: AU Date of ref document: 20091019 Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13129613 Country of ref document: US |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09827460 Country of ref document: EP Kind code of ref document: A1 |